{"id":458,"date":"2024-06-27T17:47:11","date_gmt":"2024-06-27T21:47:11","guid":{"rendered":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=458"},"modified":"2024-06-27T17:47:11","modified_gmt":"2024-06-27T21:47:11","slug":"the-changing-beauty-regulatory-landscape","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2024\/06\/27\/the-changing-beauty-regulatory-landscape\/","title":{"rendered":"The Changing Beauty Regulatory Landscape"},"content":{"rendered":"

Duane Morris attorney\u00a0Kelly Bonner<\/a> was quoted in an article in WWD on June 25, 2024.<\/p>\n

“A big deadline in the\u00a0beauty<\/a>\u00a0and personal care regulatory landscape is fast approaching, with much more to come \u2014 although some experts believe this still isn\u2019t enough.<\/p>\n

Under the Modernization of Cosmetics Regulation Act, or MoCRA, passed by Congress at the end of 2022, cosmetics companies across the U.S. are required to register their facilities to the Food and Drug Administration by Monday, pushed back from the original deadline of December. They must also list each marketed cosmetic product, including product ingredients, and provide any updates annually. […]<\/p>\n

As for what else is still to come, the industry is awaiting the FDA to issue guidance on good manufacturing practices, set to be published in 2025.<\/p>\n

On this, Kelly A. Bonner, an associate at law firm Duane Morris, said: \u201cThey\u2019re not reinventing the wheel. There are standards out there. It\u2019s just going to be what the FDA say is the standard in the United States.\u201d […]<\/p>\n

\n
\n

Bonner, for one, believes the industry has been taking the changes seriously and that the goal for the FDA is to get through the first few years of MoCRA and then take stock.<\/p>\n

\u201cUltimately FDA is going to take a hard look at it and think, \u2018OK, what are our enforcement priorities now that we have the data, now that we\u2019ve got everything in place? How do we tweak this? How do we refine this to better assist the industry, to better aid consumers?’\u201d<\/p>\n

To read the full text of this article, please\u00a0visit the\u00a0WWD<\/em>\u00a0website<\/a><\/p>\n

 <\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Duane Morris attorney\u00a0Kelly Bonner was quoted in an article in WWD on June 25, 2024. “A big deadline in the\u00a0beauty\u00a0and personal care regulatory landscape is fast approaching, with much more to come \u2014 although some experts believe this still isn\u2019t enough. Under the Modernization of Cosmetics Regulation Act, or MoCRA, passed by Congress at the … <\/p>\n

Continue reading “The Changing Beauty Regulatory Landscape”<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[628,639,641,630],"ppma_author":[521],"class_list":["post-458","post","type-post","status-publish","format-standard","hentry","category-general","tag-cosmetics","tag-kelly-bonner","tag-mocra","tag-regulatory"],"authors":[{"term_id":521,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=458"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/458\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=458"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}